Post Market Clinical Study of an Intense Pulsed Light (IPL) Medical Device as Treatment for Excessive Hairiness, Vascular and Pigmented Lesions, and Acne Vulgaris

What this Trial Is About

Researchers are evaluating the use of the ANTHÉLIA intense pulsed light (IPL) medical device to treat various skin disorders including excessive hairiness (such as hirsutism and hypertrichosis), vascular lesions like rosacea, pigmented lesions including lentigo and melasma, and acne vulgaris. The IPL device has been FDA-cleared since 1995 and is known for its cost-effectiveness and versatility compared to single-spectrum lasers, leading to its widespread use in different clinical settings. Participants in this study receive treatment with the ANTHÉLIA IPL device designed to target these skin conditions. The device is used on affected areas such as legs, arms, bikini line, axilla for hairiness; face and limbs for vascular lesions; cheeks, back, hands, arms, and legs for pigmented lesions; and the face for acne vulgaris. Treatments are scheduled and monitored up to 18 months for excessive hairiness and up to 4 months for vascular lesions, pigmented lesions, and acne. During the study, participants undergo regular evaluations to assess the effectiveness of the treatment on their skin condition. Researchers measure outcomes related to the reduction of excessive hairiness, improvement of vascular and pigmented lesions, and acne severity. Participants are monitored for safety and adherence, including protection from sun exposure during and after treatment for acne patients. The total observation period varies depending on the condition being treated, with follow-up extending up to 18 months for some outcomes.

Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder